Screening Cysteine Protease inhibitors for NTD drug discovery
Cathepsins have been identified as potential drug targets across a range of infectious organisms. Drs. Caffrey, McKerrow, and Dr. Rosenthal were interested in screening cathepsin inhibitors against a selection of parasitic organisms. BVGH connected them with AstraZeneca, which provided cysteine protease inhibitors for screening against both human and parasitic enzyme targets.